Free tool
FAERS Monitor: Camzyos
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214998 or its brand name (Camzyos, Mavacamten). Reports on generic versions are filed under their own applications.
Reports
6,048
Serious
2,643
44% of reports
Hospitalization
1,161
Death reported
164
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue442
- dyspnoea427
- atrial fibrillation370
- product dose omission issue362
- dizziness353
- product use issue268
- off label use230
- ejection fraction decreased224
- therapy interrupted196
- chest pain194
- palpitations182
- headache174
- peripheral swelling171
- nasopharyngitis153
- weight increased150
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2022 | 390 |
| 2023 | 825 |
| 2024 | 1,052 |
| 2025 | 1,458 |
| 2026 | 2,323 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,111 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| ejection fraction decreasedSignal | 224 | 50.8 | 44.7 | 10,743 |
| atrial fibrillationSignal | 370 | 13.3 | 12.0 | 4,185 |
| therapy interruptedSignal | 196 | 9.6 | 8.3 | 1,495 |
| palpitationsSignal | 182 | 5.4 | 4.7 | 653 |
| product use issueSignal | 268 | 5.0 | 4.4 | 851 |
| product dose omission issueSignal | 362 | 4.3 | 3.9 | 920 |
| peripheral swellingSignal | 171 | 3.9 | 3.3 | 362 |
| chest painSignal | 194 | 3.6 | 3.2 | 373 |
| nasopharyngitisSignal | 153 | 2.9 | 2.5 | 188 |
| dyspnoeaSignal | 427 | 2.6 | 2.4 | 439 |
| dizzinessSignal | 353 | 2.5 | 2.2 | 312 |
| weight increasedSignal | 150 | 2.3 | 2.0 | 114 |
| fatigue | 442 | 2.0 | 1.8 | 220 |
| headache | 174 | 1.0 | 0.8 | 0 |
| off label use | 230 | 0.9 | 0.8 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.